Researchers in Australia have been given approval to conduct clinical trials regarding a nasal spray that may increase the occurrence of orgasm for women. The spray is known as Tefina. The Australian trials of Tefina are to due start recruiting participants within the coming month, while there are already on-going trials in in Canada and USA.
The spray, which contains a testosterone gel, is fast absorbing and its effects are intended to last for a few hours. If approved, it would be recommended for the times when a woman anticipates sexual activity. Despite containing testosterone, the treatment does not appear to have side effects such as deepening of the voice, increased facial hair or acne.
Anorgasmia, which is a condition where an individual is unable to achieve orgasm despite adequate stimulation, is thought to occur in up to 1 in 3 pre-menopausal women. Anorgasmia is most commonly treated with psychotherapy or sex therapy, but there are no medications that are prescribed with direct relevance to anorgasmia. Therefore, the news of a new treatment is likely to be a cause for optimism among the affected individuals. However, clinical trials tend to be rather lengthy and the results would still need to go through various approval processes. As such, there may be some time before the treatment is out on the market.